RYTM FY 2025 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$190M+45.8% YoY

Gross Profit

$170M89.7% margin

Operating Income

-$192M-101.2% margin

Net Income

-$197M-103.6% margin

EPS (Diluted)

$-3.11

Cash Flow

Operating Cash Flow

-$116M

Free Cash Flow

-$117M

Stock-Based Comp.

$67M

Balance Sheet

Total Assets

$481M

Total Liabilities

$342M

Stockholders' Equity

$139M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$190M	$130M	+45.8%
Gross Profit	$170M	$117M	+45.8%
Operating Income	-$192M	-$266M	+27.7%
Net Income	-$197M	-$261M	+24.6%